The estimated Net Worth of Ralph Brandenberger is at least $644 Thousand dollars as of 18 June 2024. Dr Brandenberger owns over 229 units of Nkarta stock worth over $511,950 and over the last 3 years he sold NKTX stock worth over $131,676.
Dr has made over 13 trades of the Nkarta stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 229 units of NKTX stock worth $1,282 on 18 June 2024.
The largest trade he's ever made was exercising 11,593 units of Nkarta stock on 8 August 2022 worth over $30,142. On average, Dr trades about 3,224 units every 65 days since 2021. As of 18 June 2024 he still owns at least 79,743 units of Nkarta stock.
You can see the complete history of Dr Brandenberger stock trades at the bottom of the page.
Dr. Ralph Brandenberger Ph.D. is the Sr. VP of Technical Operations at Nkarta.
Dr D is 51, he's been the Sr. VP of Technical Operations of Nkarta since . There are 2 older and 2 younger executives at Nkarta. The oldest executive at Nkarta, Inc. is Paul J. Hastings, 61, who is the CEO, Pres & Director.
Ralph's mailing address filed with the SEC is C/O NKARTA, INC., 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Nkarta have traded over $2,620,353 worth of Nkarta stock and bought 14,255,554 units worth $205,999,973 . The most active insiders traders include Plc Gsk, Ali Behbahani, and Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of $1,501,195. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth $27,168.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta executives and other stock owners filed with the SEC include: